Humalog Related Published Studies
Well-designed clinical trials related to Humalog (Insulin Lispro)
Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. [2008.03.29]
A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. [2008.02]
A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. [2008.02]
Evaluation of the pituitary function with insulin tolerance (hypoglycaemia) testing: are there any differences using insulin lispro compared to regular insulin? [2008]
A morning dose of insulin glargine prevents nocturnal ketosis after postprandial interruption of continuous subcutaneous insulin infusion with insulin lispro. [2007.12]
AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. [2007.07]
A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone. [2007.07]
Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. [2007.03]
Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. [2007]
Insulins and oral hypoglycemic agents in pregnancy. [2006.11]
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. [2006.05]
Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. [2006.05]
Glycemic control with regular versus lispro insulin sliding scales in hospitalized Type 2 diabetics. [2006.05]
Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. [2006.03]
Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes. [2006.02]
The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. [2005.12]
Efficacy and safety of insulin glulisine in patients with type 1 diabetes. [2005.11]
Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. [2005.10]
Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. [2005.09]
Exercise with and without an insulin pump among children and adolescents with type 1 diabetes mellitus. [2005.09]
Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. [2005.09]
Assessment of dose selection attributes with audible notification in insulin pen devices. [2005.08]
Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. [2005.08]
A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. [2005.07]
Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system. [2005.05]
Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes. [2005.05]
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. [2005.05]
Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. [2005.04]
Optimal insulin pump dosing and postprandial glycemia following a pizza meal using the continuous glucose monitoring system. [2005.04]
Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. [2004.12]
Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. [2004.11]
Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. [2004.09.01]
Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes. [2004.09]
The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes. [2004.06]
A randomised controlled trial of insulin lispro given before or after meals in pregnant women with type 1 diabetes--the effect on glycaemic excursion. [2004.06]
Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. [2004.04]
Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. [2004.04]
Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. [2004.03]
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. [2004.01]
Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study. [2004]
Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. [2003.12]
The use of information technology for the management of intensive insulin therapy in type 1 diabetes mellitus. [2003.12]
Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. [2003.11.10]
A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes. [2003.11]
Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. [2003.11]
Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes. [2003.11]
Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. [2003.11]
Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. [2003.09]
Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. [2003.08]
Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. [2003.06]
Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus. [2003.06]
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. [2003.05]
Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes. [2003.04]
Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. [2003.03]
Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. [2003.03]
A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. [2003.02]
Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy. [2003.02]
Impact of bedtime snack composition on prevention of nocturnal hypoglycemia in adults with type 1 diabetes undergoing intensive insulin management using lispro insulin before meals: a randomized, placebo-controlled, crossover trial. [2003.01]
Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. [2003]
Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. [2002.11]
Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin. [2002.11]
A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. [2002.11]
Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. [2002.11]
Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs. [2002.06]
Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. [2002.05]
Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. [2002.04]
Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. [2002.04]
Additional lunchtime basal insulin during insulin lispro intensive therapy in a randomized, multicenter, crossover study in adults : a real-life design. [2002.04]
Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen? [2002.03]
Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. [2002.03]
Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. [2002.01]
Insulin lispro improves postprandial glucose control in patients with diabetes mellitus. [2002]
Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes. [2002]
A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. [2001.12]
A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. [2001.11]
Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. [2001.11]
Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide. [2001.10]
Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. [2001.10]
[Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes. Pharmacoeconomic analysis of cost-effectiveness] [2001.08]
Post-prandial insulin lispro vs. human regular insulin in prepubertal children with Type 1 diabetes mellitus. [2001.08]
Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. [2001.07]
Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin. [2001.07]
Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes. [2001.07]
Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. [2001.06]
Lispro insulin in type 1 diabetic patients on a Mediterranean or normal diet: a randomized, cross-over comparative study with regular insulin. [2001.06]
Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes. [2001.06]
Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. [2001.04]
Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). [2001.04]
Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. [2000.12]
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. [2000.12]
A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. [2000.11]
Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. [2000.09]
Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study. [2000.05]
Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: no favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction. [2000.05]
Use of insulin pump therapy at nighttime only for children 7-10 years of age with type 1 diabetes. [2000.05]
A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. [2000.03]
Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. [2000.02]
Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro. [2000.01]
Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. [1999.10]
Insulin lispro (Lys(B28), Pro(B29) in the treatment of diabetes during the fasting month of Ramadan. Ramadan Study Group. [1999.10]
Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. [1999.10]
|
